Educational Workshop with Dr Matthias Orth
The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.
The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.
Educational Workshop with Dr. Barbara De la Salle
Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.
Sebia specializes in providing testing solutions for a range of diseases, including Diabetes and Multiple Myeloma. Learn about the impact of these diseases and the medical solutions available.
Corgenix, a Sebia Group company, CAP/CLIA clinical laboratory, positions Sebia to globally commercialize M-inSight®, a novel non-invasive liquid biopsy assay for Minimal Residual Disease (MRD) monitoring in multiple myeloma